QQQ $ 619.69 $ -0.93 (-0.15 %)
DIA $ 477.07 $ 2.96 (0.62 %)
SPY $ 680.70 $ 0.72 (0.11 %)
TLT $ 89.97 $ 0.03 (0.03 %)
GLD $ 378.54 $ -1.41 (-0.37 %)
$ 4.53
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-05-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 03-13-2024 12-31-2023 10-K
9 11-03-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-08-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-09-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 03-20-2020 12-31-2019 10-K
25 10-31-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-13-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-14-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 protara-therapeutics-q3-eps-031-beats-038-estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of ...

 protara-therapeutics-q2-eps-035-beats-041-estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of ...

 jones-trading-initiates-coverage-on-protara-therapeutics-with-buy-rating-announces-price-target-of-21

Jones Trading analyst Soumit Roy initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Buy rating and announces Pr...

 protara-therapeutics-q1-eps-029-beats-045-estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-protara-therapeutics-maintains-23-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 ...

 reported-saturday-protara-therapeutics-shares-interim-results-highlighting-durable-clinical-responses-with-tara-002-in-high-risk-nmibc

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unrespons...

 protara-therapeutics-announces-conference-call-and-webcast-to-review-interim-data-from-phase-2-advanced-2-trial-of-tara-002-in-patients-with-nmibc-on-monday-april-28-2025

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing tran...

 scotiabank-initiates-coverage-on-protara-therapeutics-with-sector-outperform-rating-announces-price-target-of-12

Scotiabank analyst George Farmer initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Sector Outperform rating an...

 cantor-fitzgerald-initiates-coverage-on-protara-therapeutics-with-overweight-rating

Cantor Fitzgerald analyst Li Watsek initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating.

 lifesci-capital-initiates-coverage-on-protara-therapeutics-with-outperform-rating-announces-price-target-of-22

LifeSci Capital initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Outperform rating and announces Price Target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION